INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA
Institut
Universidad Católica de Valencia San Vicente Mártir
Valencia, EspañaPublications en collaboration avec des chercheurs de Universidad Católica de Valencia San Vicente Mártir (19)
2024
-
Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis in HLA-Matched and Haploidentical Donor Transplantation for Patients with Hodgkin Lymphoma: A Comparative Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation
Transplantation and Cellular Therapy, Vol. 30, Núm. 2, pp. 210.e1-210.e14
2023
-
A glimpse into relapsed refractory multiple myeloma treatment in real-world practice in Spain: the GeminiS study
Hematology (United Kingdom), Vol. 28, Núm. 1
-
A reproducible and repeatable digital method for quantifying nasal and sinus airway changes following suture palatine expansion
Sleep and Breathing, Vol. 27, Núm. 3, pp. 1175-1183
-
Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS
Blood cancer journal
-
Socio-Emotional Competencies Required by School Counsellors to Manage Disruptive Behaviours in Secondary Schools
Children, Vol. 10, Núm. 2
2022
-
Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma; Insights into Its Potential Role in the Era of New Immunotherapeutic and Targeted Therapies: The GETH/GELTAMO Experience
Cancers, Vol. 14, Núm. 11
-
Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 27, pp. 3151-3161
-
Severity and duration of allergic conjunctivitis: are they associated with severity and duration of allergic rhinitis and asthma?
European Annals of Allergy and Clinical Immunology, Vol. 54, Núm. 6, pp. 277-283
2020
-
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma
Blood, Vol. 136, Núm. 2, pp. 199-209
-
Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 38, Núm. 8, pp. 784-792
2017
-
Retos del empleo de la secuenciación masiva de nueva generación (NGS) de la macrofauna bentónica para la evaluación de la calidad ambiental marina
Nereis: revista iberoamericana interdisciplinar de métodos, modelización y simulación, Núm. 9, pp. 81-90
2016
-
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): An open-label, randomised, phase 2 trial
The Lancet, Vol. 387, Núm. 10027, pp. 1551-1560
-
Phase I/II study of weekly PM00104 (Zalypsis®) in patients with relapsed/refractory multiple myeloma
British Journal of Haematology
2015
-
Bendamustine, bortezomib and prednisone for the treatment of patients with newly diagnosed multiple myeloma: Results of a prospective phase 2 Spanish/PETHEMA trial
Haematologica, Vol. 100, Núm. 8, pp. 1096-1102
-
Clinical management and use of health care resources in the treatment of nasal polyposis in Spanish allergy centers: The POLAR study
Journal of Investigational Allergology and Clinical Immunology, Vol. 25, Núm. 4, pp. 276-282
-
Consensus document on allergic conjunctivitis (DECA)
Journal of Investigational Allergology and Clinical Immunology, Vol. 25, Núm. 2, pp. 94-106
-
Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations
Leukemia Research Reports, Vol. 4, Núm. 2, pp. 64-69
2014
2013
-
Intravenous Busulfan and Melphalan as a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Matched Comparison to a Melphalan-Only Approach
Biology of Blood and Marrow Transplantation, Vol. 19, Núm. 1, pp. 69-74